JP7171971B1 - エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 - Google Patents

エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 Download PDF

Info

Publication number
JP7171971B1
JP7171971B1 JP2022531536A JP2022531536A JP7171971B1 JP 7171971 B1 JP7171971 B1 JP 7171971B1 JP 2022531536 A JP2022531536 A JP 2022531536A JP 2022531536 A JP2022531536 A JP 2022531536A JP 7171971 B1 JP7171971 B1 JP 7171971B1
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
epinastine
present
acid
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022531536A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022138842A1 (https=
JPWO2022138842A5 (https=
Inventor
豊実 藤澤
紘之 池田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Santen Pharmaceutical Co Ltd
Original Assignee
Santen Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co Ltd filed Critical Santen Pharmaceutical Co Ltd
Publication of JPWO2022138842A1 publication Critical patent/JPWO2022138842A1/ja
Priority to JP2022176040A priority Critical patent/JP2023011818A/ja
Application granted granted Critical
Publication of JP7171971B1 publication Critical patent/JP7171971B1/ja
Publication of JPWO2022138842A5 publication Critical patent/JPWO2022138842A5/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022531536A 2020-12-24 2021-12-23 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物 Active JP7171971B1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022176040A JP2023011818A (ja) 2020-12-24 2022-11-02 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020215228 2020-12-24
JP2020215228 2020-12-24
PCT/JP2021/047943 WO2022138842A1 (ja) 2020-12-24 2021-12-23 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022176040A Division JP2023011818A (ja) 2020-12-24 2022-11-02 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Publications (3)

Publication Number Publication Date
JPWO2022138842A1 JPWO2022138842A1 (https=) 2022-06-30
JP7171971B1 true JP7171971B1 (ja) 2022-11-15
JPWO2022138842A5 JPWO2022138842A5 (https=) 2022-12-05

Family

ID=82158746

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022531536A Active JP7171971B1 (ja) 2020-12-24 2021-12-23 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP2022176040A Pending JP2023011818A (ja) 2020-12-24 2022-11-02 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022176040A Pending JP2023011818A (ja) 2020-12-24 2022-11-02 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Country Status (7)

Country Link
US (1) US20240058356A1 (https=)
EP (1) EP4268825A4 (https=)
JP (2) JP7171971B1 (https=)
KR (1) KR20230124625A (https=)
CN (1) CN116744904A (https=)
TW (1) TW202241448A (https=)
WO (1) WO2022138842A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023011818A (ja) * 2020-12-24 2023-01-24 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP2023126180A (ja) * 2022-02-28 2023-09-07 久光製薬株式会社 ジャー容器用のブテナフィン含有クリーム剤

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522053A (ja) * 2003-04-04 2006-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 皮膚疾患治療用エピナスチン含有医薬組成物
JP2016513723A (ja) * 2013-03-14 2016-05-16 パナシア ファーマシューティカルズ， インコーポレイテッド 化学療法誘発認知障害の処置
WO2018203424A1 (ja) * 2017-05-01 2018-11-08 参天製薬株式会社 点眼剤
JP2020055799A (ja) * 2018-09-28 2020-04-09 ロート製薬株式会社 眼科組成物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ242358A (en) * 1991-05-10 1994-03-25 Allergan Inc Use of thiol compounds to inhibit deposits on a contact lens
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
KR20050092429A (ko) 2003-01-22 2005-09-21 니찌방 가부시기가이샤 안질환 치료용 경피 흡수형 제제, 그 사용, 및 안질환치료약의 눈의 국소 조직으로의 이행 방법
JP5021155B2 (ja) * 2003-08-01 2012-09-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング エピナスチンと１種以上のさらなる抗−ｈ１−ヒスタミン類との組合せを含む皮膚疾患治療用製薬組成物
CN101217948A (zh) * 2005-07-08 2008-07-09 千寿制药株式会社 包含依匹那丁的透皮吸收眼科制剂
EP1985298A1 (en) * 2007-04-24 2008-10-29 Azad Pharma AG Ophtalmic oil-in-water emulsions containing prostaglandins
ES2964555T3 (es) * 2009-08-24 2024-04-08 Stealth Biotherapeutics Inc Péptido para uso en la prevención o tratamiento de la degeneración macular
EP3302426A4 (en) * 2015-05-29 2018-12-05 Sydnexis, Inc. D2o stabilized pharmaceutical formulations
JP2019108320A (ja) * 2018-10-31 2019-07-04 参天製薬株式会社 ソフトコンタクトレンズの変質を抑制する眼科用組成物
JP6736752B2 (ja) * 2019-12-17 2020-08-05 参天製薬株式会社 エピナスチン含有点眼液
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522053A (ja) * 2003-04-04 2006-09-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 皮膚疾患治療用エピナスチン含有医薬組成物
JP2016513723A (ja) * 2013-03-14 2016-05-16 パナシア ファーマシューティカルズ， インコーポレイテッド 化学療法誘発認知障害の処置
WO2018203424A1 (ja) * 2017-05-01 2018-11-08 参天製薬株式会社 点眼剤
JP2020055799A (ja) * 2018-09-28 2020-04-09 ロート製薬株式会社 眼科組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023011818A (ja) * 2020-12-24 2023-01-24 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
JP2023126180A (ja) * 2022-02-28 2023-09-07 久光製薬株式会社 ジャー容器用のブテナフィン含有クリーム剤
JP7638310B2 (ja) 2022-02-28 2025-03-03 久光製薬株式会社 ジャー容器用のブテナフィン含有クリーム剤

Also Published As

Publication number Publication date
JPWO2022138842A1 (https=) 2022-06-30
EP4268825A1 (en) 2023-11-01
US20240058356A1 (en) 2024-02-22
EP4268825A4 (en) 2024-12-11
TW202241448A (zh) 2022-11-01
EP4268825A9 (en) 2025-10-01
JP2023011818A (ja) 2023-01-24
CN116744904A (zh) 2023-09-12
KR20230124625A (ko) 2023-08-25
WO2022138842A1 (ja) 2022-06-30

Similar Documents

Publication Publication Date Title
ES2450423T3 (es) Composición farmacéutica que comprende propofol
JP6670283B2 (ja) タペンタドールを含む半固形の水性医薬組成物
RU2497516C2 (ru) Композиция для местного введения
US20140113971A1 (en) Topical NSAID Compositions Having Sensate Component
WO1993008798A1 (en) Pentadimine transdermal composition and patch
RS57344B1 (sr) Farmaceutska dozna forma koja sadrži 6'-fluoro-(n-metil- ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za lečenje neuropatskog bola
JP7171971B1 (ja) エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物
US20110237674A1 (en) Topical nsaid compositions having sensate component
JP2021095420A (ja) エピナスチン又はその塩を含有する水性医薬組成物
JP7124248B1 (ja) エピナスチン又はその塩を含有する塗布投与用医薬組成物
KR20250133899A (ko) 국소 약학적 조성물 및 이의 용도
JP6963651B2 (ja) エピナスチン又はその塩を含有する水性組成物
WO2025205960A1 (ja) エピナスチン又はその塩を含有する経皮投与用医薬組成物と抗アレルギー薬との組み合わせ
WO2007086582A1 (ja) ２２－オキサ－１α,２５－ジヒドロキシビタミンＤ3を含有する水中油型乳剤性ローション剤およびそれを用いた皮膚疾患の治療方法
JP2025036319A (ja) クロルフェニラミンマレイン酸塩を含有する医薬組成物
CN116669705A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
HK40097614A (en) Pharmaceutical composition for topical administration containing epinastine or salt thereof
JP2022515569A (ja) フェノルドパムの安定な局所用組成物
JP7512365B2 (ja) 油性外用液
HK40091801A (zh) 含有依匹斯汀或其盐的涂布施予用医药组合物
JP2024162159A (ja) 外用組成物
JP2024090835A (ja) 組織移行性を向上させるエピナスチン含有水性組成物
JP2024025725A (ja) 組成物
JP2024025726A (ja) 組成物
BR112020000379A2 (pt) emulsão de óleo em água

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220527

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220527

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220915

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221004

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221102

R150 Certificate of patent or registration of utility model

Ref document number: 7171971

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153